|
|
||||||||
Original Articles |
We wanted to evaluate whether lung deposition of budesonide and terbutaline sulphate differs, and to determine lung deposition of budesonide inhaled at different peak inspiratory flows, through Turbuhaler. Lung deposition of budesonide, a lipophilic substance, and of terbutaline sulphate, a hydrophilic substance, was therefore compared, after administration via an inspiratory flow-driven, multi-dose, powder inhaler (Turbuhaler, Astra Draco AB) to 10 healthy volunteers. The radionuclide 99mTc was used to label drug particles, and radioactivity, indicating drug deposition, was measured using a gamma camera. Budesonide was inhaled at a normal flow of 58 l.min-1 and at a slow flow of 36 l-min-1. At the faster flow, a mean +/- SD 27.7 +/- 9.5% of the metered dose was deposited in the lung and at the slower flow 14.8 +/- 3.3% was deposited (p < 0.001). Mean lung deposition of terbutaline sulphate inhaled at 57 l.min-1 was 27.0 +/- 7.7%. We conclude that inspiratory flow has an important effect on lung deposition, but water solubility appears to have no effect.
This article has been cited by other articles:
![]() |
W. Janssens, P. VandenBrande, E. Hardeman, E. De Langhe, T. Philps, T. Troosters, and M. Decramer Inspiratory flow rates at different levels of resistance in elderly COPD patients Eur. Respir. J., January 1, 2008; 31(1): 78 - 83. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Brand, T. Meyer, T. Weuthen, W. Timmer, E. Berkel, G. Wallenstein, and G. Scheuch Lung Deposition of Radiolabeled Tiotropium in Healthy Subjects and Patients With Chronic Obstructive Pulmonary Disease J. Clin. Pharmacol., October 1, 2007; 47(10): 1335 - 1341. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Jarvis, P. W. Ind, and R. J. Shiner Inhaled therapy in elderly COPD patients; time for re-evaluation? Age Ageing, March 1, 2007; 36(2): 213 - 218. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Derendorf, R. Nave, A. Drollmann, F. Cerasoli, and W. Wurst Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur. Respir. J., November 1, 2006; 28(5): 1042 - 1050. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Winkler, G. Hochhaus, and H. Derendorf How the Lung Handles Drugs: Pharmacokinetics and Pharmacodynamics of Inhaled Corticosteroids Proceedings of the ATS, December 1, 2004; 1(4): 356 - 363. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. G. Cochrane, M. V. Bala, K. E. Downs, J. Mauskopf, and R. H. Ben-Joseph Inhaled Corticosteroids for Asthma Therapy: Patient Compliance, Devices, and Inhalation Technique Chest, February 1, 2000; 117(2): 542 - 550. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. BARNES, S. PEDERSEN, and W. W. BUSSE Efficacy and Safety of Inhaled Corticosteroids . New Developments Am. J. Respir. Crit. Care Med., March 1, 1998; 157(3): S1 - 53. [Full Text] [PDF] |
||||
![]() |
P. J. THOMPSON Drug Delivery to the Small Airways Am. J. Respir. Crit. Care Med., May 1, 1997; 157(5): 199 - 202. [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |